Cargando…
Periostin: a promising target of therapeutical intervention for prostate cancer
BACKGROUND: In our recent study, Periostin was up-regulated in prostate cancer(PCa) compared with benign prostate hyperplasia (BPH) by proteomics analysis of prostate biopsies. We investigated the effect of sliencing Periostin by RNA interference (RNAi) on the proliferation and migration of PCa LNCa...
Autores principales: | Sun, Chuanyu, Zhao, Xiaojun, Xu , Ke, Gong, Jian, Liu, Weiwei, Ding, Weihong, Gou, Yuancheng, Xia, Guowei, Ding, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146429/ https://www.ncbi.nlm.nih.gov/pubmed/21714934 http://dx.doi.org/10.1186/1479-5876-9-99 |
Ejemplares similares
-
Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy
por: Sun, Chuanyu, et al.
Publicado: (2011) -
Retroperitoneal Laparoscopic Ureterolithotomy for Proximal Ureteral Calculi in Selected Patients
por: Hu, Qingfeng, et al.
Publicado: (2014) -
The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer
por: Chen, Zhongqing, et al.
Publicado: (2012) -
EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
por: Wang, Hui, et al.
Publicado: (2018) -
Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)